New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
09:00 EDTALKSAlkermes falls 7%
Alkermes is down 7%, or $1.61, to $21.44
News For ALKS From The Last 14 Days
Check below for free stories on ALKS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
16:35 EDTALKSAlkermes recent pullback a buying opportunity, says Leerink
Leerink does not expect any surprises when Alkermes reports Q1 results and views the recent pullback in shares as a buying opportunity. The firm reiterates an Outperform rating on the stock with a $66 price target.
April 10, 2014
10:00 EDTALKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:55 EDTALKSAlkermes upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
April 9, 2014
07:49 EDTALKSAlkermes price target raised to $66 from $60 at Leerink
Subscribe for More Information
April 8, 2014
14:43 EDTALKSAlkermes price target rasied to $66 from $60 at Leerink
09:00 EDTALKSAlkermes rises 7.4%
Alkermes is up 7.4%, or $3.03, to $44.13
07:47 EDTALKSAlkermes to host conference call
Subscribe for More Information
07:04 EDTALKSAlkermes announces phase 3 'positive' results from aripiprazole lauroxil study
Alkermes announced "positive" topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale total scores at week 12, compared to placebo, which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application to the U.S. Food and Drug Administration in 3Q14. In addition to meeting the prespecified primary efficacy endpoint, the study also met the prespecified key secondary endpoint of improvement on the Clinical Global Impression-Improvement scale versus placebo at week 12. Aripiprazole lauroxil was generally well tolerated in the phase 3 study, and the safety profile of aripiprazole lauroxil was similar to that reported with oral aripiprazole. The most common adverse events in the study were insomnia, akathisia and headache. Alkermes will present data from the phase 3 study at an upcoming medical meeting and submit the results for publication in a peer-reviewed journal.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use